Neumora Therapeutics Inc (NMRA)

Neumora tops Q4 earnings forecasts as pipeline advances, shares slipMarch 30, 2026 8:45 AM
IH Market News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) on Monday reported fourth-quarter results that came in ahead of analyst estimates.Despite the earnings beat, the company’s stock declined about 2.15% in premarket trading as investors assessed its cash position and ongoing pipeline developments.The clinical-stage biopharmaceutical company posted a quarterly loss of $0.35 per share, outperforming the analyst consensus estimate of a $0.47 per share loss.Neumora recorded a net loss of $59.4 million for the fourth quarter of 2025, compared with $58.8 million during the same period a year earlier. For the full year, the company reported a net loss of $236.9 million in 2025, narrowing slightly from $243.8 million in 2024.At the end of the quarter, Neumora held $182.5 million in cash, cash equivalents and marketable securities. The company said this capital is expected to fund operations through the third quarter of 2027. The balance declined from $307.6 million at the close of 2024.Research and development spending totaled $44.7 million in the fourth quarter, down from $45.9 million in the same period last year, largely reflecting lower costs tied to the navacaprant program after completion of the KOASTAL-1 study. General and administrative expenses also decreased year-over-year to $13.8 million from $17.0 million.“We saw significant progress in 2025, laying the foundation for a catalyst-rich year ahead as we advance our pipeline of next-generation therapies for people living with brain diseases,” said Paul L. Berns, co-founder, chairman and chief executive officer of Neumora.The company also announced that enrollment has been completed for its KOASTAL-2 and KOASTAL-3 studies in the first quarter of 2026, with topline results expected in the second quarter of the year. Additionally, Neumora identified NMRA-898 as the lead candidate within its M4 franchise for schizophrenia treatment, with data anticipated in the second half of 2026.Neumora Therapeutics stock price

Original: Neumora tops Q4 earnings forecasts as pipeline advances, shares slip

NMRA.....................https://stockcharts.com/sc3/ui/?s=NMRA&p=W&b=5&g=0&id=p86431144783

NMRA..................................https://stockcharts.com/sc3/ui/?s=NMRA&p=W&b=5&g=0&id=p86431144783

NMRA...............................https://stockcharts.com/sc3/ui/?s=NMRA&p=W&b=5&g=0&id=p86431144783

NMRA....................................https://stockcharts.com/sc3/ui/?s=NMRA&p=W&b=5&g=0&id=p86431144783

nmra........................................https://stockcharts.com/sc3/ui/?s=NMRA&p=W&b=5&g=0&id=p86431144783

$3.15 cash out .Pump dump and offering soon need to raise cash for 2026 

Looks to be a good price

to start investing. Most analysts are callingh for a $7 price.

NMRA.....................https://stockcharts.com/sc3/ui/?s=NMRA&p=W&b=5&g=0&id=p86431144783

NMRA....................................................https://stockcharts.com/h-sc/ui?s=NMRA&p=W&b=5&g=0&id=p86431144783

This one looks pretty interesting...Any thoughts?

NMRA.....................................................https://stockcharts.com/h-sc/ui?s=NMRA&p=W&b=5&g=0&id=p86431144783

$NMRA . Trades below CASH. 7 drugs in pipeline. Recently took a 80% haircut on bad initial data on one of three phase III. Oversold. RSI low. Bounce.

nmra...................................under 2

NMRA........................https://stockcharts.com/h-sc/ui?s=NMRA&p=W&b=5&g=0&id=p86431144783

NMRA.............................................https://stockcharts.com/h-sc/ui?s=NMRA&p=W&b=5&g=0&id=p86431144783

nmra..........................under 2.00

1.95 -81%
$NMRA P2b retrospective data mining in shock turn of events doesn't translate to prospective P3 stat sig data. What a surprise.— Biotech Shoutouts (@BiotechSho99376) January 2, 2025
$NMRA right to cash level, same drug bi polar next pic.twitter.com/nfXRhMULQH— MonkeyGeniusCapital (@bearsbounce) January 2, 2025
$NMRA whiff - pic.twitter.com/y0cVEhb2fN— Sports_Bios (@Sports_bios) January 2, 2025

NMRA under $15

NMRA under $10

NMRA under &10